Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

330 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial.
Widschwendter P, Friedl TW, Schwentner L, DeGregorio N, Jaeger B, Schramm A, Bekes I, Deniz M, Lato K, Weissenbacher T, Kost B, Andergassen U, Jueckstock J, Neugebauer J, Trapp E, Fasching PA, Beckmann MW, Schneeweiss A, Schrader I, Rack B, Janni W, Scholz C. Widschwendter P, et al. Among authors: jaeger b. Breast Cancer Res. 2015 Sep 18;17(1):129. doi: 10.1186/s13058-015-0639-3. Breast Cancer Res. 2015. PMID: 26385214 Free PMC article. Clinical Trial.
Evaluation of two different analytical methods for circulating tumor cell detection in peripheral blood of patients with primary breast cancer.
Jaeger BA, Jueckstock J, Andergassen U, Salmen J, Schochter F, Fink V, Alunni-Fabbroni M, Rezai M, Beck T, Beckmann MW, Friese K, Friedl TW, Janni W, Rack B. Jaeger BA, et al. Biomed Res Int. 2014;2014:491459. doi: 10.1155/2014/491459. Epub 2014 Apr 8. Biomed Res Int. 2014. PMID: 24800234 Free PMC article. Clinical Trial.
Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer.
Kiechl S, Schramek D, Widschwendter M, Fourkala EO, Zaikin A, Jones A, Jaeger B, Rack B, Janni W, Scholz C, Willeit J, Weger S, Mayr A, Teschendorff A, Rosenthal A, Fraser L, Philpott S, Dubeau L, Keshtgar M, Roylance R, Jacobs IJ, Menon U, Schett G, Penninger JM. Kiechl S, et al. Among authors: jaeger b. Oncotarget. 2017 Jan 17;8(3):3811-3825. doi: 10.18632/oncotarget.14013. Oncotarget. 2017. PMID: 28002811 Free PMC article.
Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer.
Schramm A, Schochter F, Friedl TWP, de Gregorio N, Andergassen U, Alunni-Fabbroni M, Trapp E, Jaeger B, Heinrich G, Camara O, Decker T, Ober A, Mahner S, Fehm TN, Pantel K, Fasching PA, Schneeweiss A, Janni W, Rack BK; SUCCESS Study Group. Schramm A, et al. Among authors: jaeger b. Clin Breast Cancer. 2017 Jul;17(4):279-285. doi: 10.1016/j.clbc.2016.11.008. Epub 2017 Jan 10. Clin Breast Cancer. 2017. PMID: 28190761 Clinical Trial.
The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial.
Jaeger BAS, Neugebauer J, Andergassen U, Melcher C, Schochter F, Mouarrawy D, Ziemendorff G, Clemens M, V Abel E, Heinrich G, Schueller K, Schneeweiss A, Fasching P, Beckmann MW, Scholz C, Friedl TWP, Friese K, Pantel K, Fehm T, Janni W, Rack B. Jaeger BAS, et al. PLoS One. 2017 Jun 6;12(6):e0173593. doi: 10.1371/journal.pone.0173593. eCollection 2017. PLoS One. 2017. PMID: 28586395 Free PMC article. Clinical Trial.
Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer.
De Gregorio A, Friedl TWP, Huober J, Scholz C, De Gregorio N, Rack B, Trapp E, Alunni-Fabbroni M, Riethdorf S, Mueller V, Schneeweiss A, Pantel K, Meier-Stiegen F, Jaeger B, Hartkopf A, Taran FA, Fasching PA, Janni W, Fehm T. De Gregorio A, et al. Among authors: jaeger b. JCO Precis Oncol. 2017 Nov;1:1-12. doi: 10.1200/PO.17.00023. JCO Precis Oncol. 2017. PMID: 35172510
Efficacy of Lapatinib in Patients with HER2-Negative Metastatic Breast Cancer and HER2-Positive Circulating Tumor Cells-The DETECT III Clinical Trial.
Fehm T, Mueller V, Banys-Paluchowski M, Fasching PA, Friedl TWP, Hartkopf A, Huober J, Loehberg C, Rack B, Riethdorf S, Schneeweiss A, Wallwiener D, Meier-Stiegen F, Krawczyk N, Jaeger B, Reinhardt F, Hoffmann O, Mueller L, Wimberger P, Ruckhaeberle E, Blohmer JU, Cieslik JP, Franken A, Niederacher D, Neubauer H, Pantel K, Janni W; DETECT Study Group. Fehm T, et al. Among authors: jaeger b. Clin Chem. 2024 Jan 4;70(1):307-318. doi: 10.1093/clinchem/hvad144. Clin Chem. 2024. PMID: 38175595 Clinical Trial.
Multiparametric Circulating Tumor Cell Analysis to Select Targeted Therapies for Breast Cancer Patients.
Franken A, Behrens B, Reinhardt F, Yang L, Rivandi M, Marass F, Jaeger B, Krawczyk N, Cieslik JP, Honisch E, Asperger H, Jeannot E, Proudhon C, Beerenwinkel N, Schölermann N, Esposito I, Dietzel F, Stoecklein NH, Niederacher D, Fehm T, Neubauer H. Franken A, et al. Among authors: jaeger b. Cancers (Basel). 2021 Nov 29;13(23):6004. doi: 10.3390/cancers13236004. Cancers (Basel). 2021. PMID: 34885114 Free PMC article.
Invasive Breast Carcinoma with Neuroendocrine Differentiation: A Single-Center Analysis of Clinical Features and Prognosis.
Krawczyk N, Röwer R, Anlauf M, Muntanjohl C, Baldus SE, Neumann M, Banys-Paluchowski M, Otten S, Luczak K, Ruckhäberle E, Mohrmann S, Hoffmann J, Kaleta T, Jaeger B, Esposito I, Fehm T. Krawczyk N, et al. Among authors: jaeger b. Geburtshilfe Frauenheilkd. 2021 Nov 18;82(1):68-84. doi: 10.1055/a-1557-1280. eCollection 2022 Jan. Geburtshilfe Frauenheilkd. 2021. PMID: 35027862 Free PMC article.
330 results